AbbVie, Amgen reach a deal on Humira biosimilar
biopharmadive | September 28, 2017
Amgen Inc. has secured the right to sell a copycat version of AbbVie's top-selling drug in the U.S. — but first, it will have to wait six years. Following more than a year of litigation concerning the intellectual property for Humira, the companies reached a settlement on Thursday. Amgen now has non-exclusive rights to market its biosimilar in most European countries starting Oct. 16, 2018 and stateside starting Jan.